跳至主要内容
临床试验/NCT00783315
NCT00783315已完成不适用

Practice-Based Opportunities for Weight Reduction Trial at Johns Hopkins

Johns Hopkins University2 个研究点 分布在 1 个国家目标入组 415 人开始时间: 2008年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
415
试验地点
2
主要终点
Weight

研究概览

简要总结

Many people who are obese also have high blood pressure, high cholesterol, or diabetes-all conditions that can increase the risk of heart disease. This study will evaluate two programs that aim to encourage weight loss among obese people who are at risk for developing heart disease.

详细描述

High blood pressure, high cholesterol, and diabetes are all conditions that increase a person's risk of developing heart disease. Many people with these conditions are also overweight, and it is recommended that such people lose weight to reduce their risk of heart disease. Previous weight loss studies have mainly examined in-person weight loss programs and not Web- or e-mail-based weight loss programs. In addition, the primary care providers of participants in these previous studies typically had no direct involvement in the programs. This study will compare two weight loss programs-an In-Person Directed (IPD) program, which is primarily comprised of in-person visits with health counselors, and a Call-Center Directed (CCD) program, which uses only telephone, Web sites, and e-mail to contact and counsel participants. These two programs will also be compared against a self-directed weight loss program, which will act as a control group. The ultimate purpose of this study is to evaluate the effectiveness of the IPD, CCD, and self-directed programs at increasing weight loss and reducing risk factors in obese people at risk of developing heart disease.

This study will enroll overweight adults who have high blood pressure, high cholesterol, or diabetes. Participants will attend a baseline study visit for weight and blood pressure measurements. They will then be randomly assigned to participate in one of the following three programs for 2 years.

  1. IPD Program: This program will be directed by health counselors from Johns Hopkins University. For Months 1 to 3, participants will attend a group or individual meeting with a counselor each week. For Months 4 to 6, meetings will be held three times a month; after Month 6, meetings will occur twice a month. Some of these meetings may be held over the phone or by e-mail. Participants will keep a food and exercise diary and they will enter their weight and calorie consumption on the study Web site. Study researchers will provide participants' doctors with relevant information on participants' weight loss.
  2. CCD Program: This program will be directed by counselors from Healthways, Inc., a company that assists individuals in managing their medical problems. All contacts will occur by phone, e-mail, or the Web; there will be no in-person visits. Participants will be able to review weight loss information on the study Web site. For Months 1 to 3, participants will contact their counselors each week. For Months 4 to 6, contact with study counselors will occur at least once a month; after Month 6, contact with study counselors will occur every other month. Participants will keep a food and exercise diary and they will enter their weight and calorie consumption on the study Web site. Study researchers will provide participants' doctors with relevant information on participants' weight loss.
  3. Self-Directed Program: In this program, study staff will meet with participants once at the beginning of the study, at which time participants will receive written information about losing weight. Participants will also receive access to a study Web site that has information about weight loss.

All participants will attend study visits at Months 6, 12, and 24 and at the end of the study, which is anticipated to be in February 2011. Study researchers will also collect information by phone at Month 18. At each study visit, participants will complete questionnaires; provide blood samples; and undergo measurements of weight, waist, and blood pressure. A portion of blood may be stored for future studies; this will be optional.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Persons who measured weight and other outcomes were masked to randomized assignment.

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hypertension, hypercholesterolemia, and/or diabetes mellitus, all of which are treated with medication, measured in the clinic, or confirmed by primary care provider (systolic blood pressure greater than or equal to 140 mm Hg, diastolic blood pressure greater than or equal to 90 mm Hg, low density lipoprotein cholesterol [LDL-C] greater than or equal to 130 mg/dL, or fasting blood sugar greater than 125 mg/dL)
  • BMI of at least 30 to 50 kg/m2 and weight less than or equal to 400 lbs
  • Willing to change diet, physical activity, and weight
  • Willing to be randomly assigned to any of the study groups
  • Patient of a participating doctor
  • Patient self-reports two doctor visits in the 12 months before study entry
  • Demonstrated use of Web and e-mail
  • Access to Internet at least 4 days per week
  • People with the following conditions are eligible to enroll in the study with primary care provider approval:
  • Diabetes mellitus
  • Prior cardiovascular disease event more than 6 months before study entry
  • Known stable cardiovascular disease or peripheral vascular disease
  • Screen positive on Rose Questionnaire

排除标准

  • Heart attack, stroke, or atherosclerotic cardiovascular disease (ASCVD) procedure in the 6 months before study entry
  • Serious medical condition that is likely to hinder accurate measurement of weight, for which weight loss is not advisable, or that would cause weight loss [e.g., end-stage renal disease (ESRD) on dialysis, cancer diagnosis or treatment in the 2 years before study entry]
  • Prior or planned bariatric surgery
  • Use of prescription weight loss medication, including off-label drugs (e.g., topiramate, bupropion, byetta) or over-the-counter orlistat in the 6 months before study entry
  • Long-term use (in the 6 months before study entry) of medications likely to cause weight gain or prevent weight loss (e.g., corticosteroids, lithium, olanzapine, risperidone, clozapine)
  • Unintentional weight loss in the 6 months before study entry (greater than or equal to 5% of body weight)
  • Intentional weight loss in the 6 months before study entry (greater than or equal to 5% of body weight)
  • Pregnant or breastfeeding in the 6 months before study entry
  • Planning to become pregnant in the 2 years after study entry
  • Planning to relocate from area in the 2 years after study entry
  • Another member of the household is a study participant or study staff member
  • Self-reported average consumption of more than 14 alcoholic drinks each week
  • Psychiatric hospitalization in the 1 year before study entry
  • Unstable angina
  • Blood pressure greater than 160/100 mm Hg

研究组 & 干预措施

1

Active Comparator

Self-Directed Weight Loss Program (Control Group)

干预措施: Self-Directed Weight Loss Program (Behavioral)

2

Experimental

Call-Center Directed (CCD) Weight Loss Program

干预措施: Call-Center Directed (CCD) Weight Loss Program (Behavioral)

3

Experimental

In-Person Directed (IPD) Weight Loss Program

干预措施: In-Person Directed (IPD) Weight Loss Program (Behavioral)

结局指标

主要结局

Weight

时间窗: Measured at Month 24

次要结局

  • Homeostasis model assessment of insulin resistance (HOMA-IR)(Measured at Month 24)
  • Framingham risk(Measured at Month 24)
  • Metabolic syndrome(Measured at Month 24)
  • Lipid levels(Measured at Month 24)
  • Hypertension control(Measured at Month 24)
  • Body mass index (BMI)(Measured at Month 24)
  • Blood pressure(Measured at Month 24)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验